Astellas, Potenza to develop new immuno-oncology therapeutics
The collaboration is aimed at advancing a portfolio consisting of programs with new mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. As part
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.